ResApp HEALTH

Digital healthcare for respiratory disease

Tony Keating
Chief Executive Officer and Managing Director
tony@resapphealth.com.au / +61 430 180 659

US Roadshow Presentation
11-13 November 2015

ASX: RAP

Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

Digital healthcare for respiratory disease

- Developing the world's first clinically-tested, regulatory-approved respiratory disease diagnostic test for smartphones
  - **No additional hardware** needed
  - Unique opportunity to integrate into **telehealth** providers' existing platforms
  - Apps to provide clinical-quality ('Gold Standard') diagnostic tests and chronic disease management tools directly to consumers and healthcare providers
- Huge global market, 700M+ doctor visits annually for respiratory disease[1]
- High levels of accuracy demonstrated in clinical proof of concept study and in multi-site clinical study underway in Perth, Australia
- Fully-funded to bring product to market in late 2016

1. Based on OECD doctor visits per capita data and assuming 10% of visits are for respiratory disease (based on US data)

ResApp HEALTH

Company overview

Capital Structure (ASX:RAP)

Shares on issue[1]	561M
Share price as of 6 November 2015	AU$0.078
Market Cap	AU$44M
Performance Shares[2]	93.75M
Options[3]	33.75M
Incentive Options[4]	25M
Cash Balance as of 30 September 2015	AU$3.4M

1. Includes 121M escrowed shares
2. Issued on achieving $20M of annual revenue or on an acquisition
3. Exercise price of 2.6c, expire 31 December 2016
4. Issued to MD, 5M options at exercise price of 2.5c, 5M at 5c and 10M at 10c, 5 year expiry; Issued to Dr Abeyratne, 3M at 5c and 2M at 10c

Board of Directors

Dr Roger Aston — Non-Executive Chairman

(Chairman of Oncosil, former CEO of Mayne Pharma, Cambridge Antibody, cofounder of pSivida Corp)

Dr Tony Keating — Managing Director and CEO

(former Director, Commercial Engagement of UniQuest, engineering management roles with Exa Corporation)

Mr Adam Sierakowski — Non-Executive Director

Mr Chris Ntoumenopoulos — Non-Executive Director

Substantial Shareholders

UniQuest Pty Ltd: 7.51%

Freeman Road: 5.34%

Top 20 Shareholders: 36.95%

ResApp HEALTH

Diagnosis of respiratory disease is the most common outcome from a visit to the doctor



Acute conditions
URTIs, influenza, bronchitis, bronchiolitis, pneumonia, pertussis, croup

Chronic Conditions
Asthma, COPD, cystic fibrosis, bronchiectasis

- **125M** doctor visits[1] in the US for respiratory disease (10% of all visits)
- **6-8M** doctor visits[2] in Australia for respiratory disease
- Est. **700M+** doctor visits globally[3] for respiratory disease
- High prevalence and growth in Asia

Currently diagnosed using stethoscope, imaging (x-ray, CT), blood and/or sputum tests

1. Ambulatory case visits, National Ambulatory Medical Care Survey 2010
2. Australian Lung Foundation
3. Based on OECD doctor visits per capita data and assuming 10% of visits are for respiratory disease (based on US data)

ResApp HEALTH

Revolutionary tool based on sound signatures

- Exclusive worldwide license to machine learning technology developed by A/Prof. Abeyratne at The University of Queensland
- Uses signatures in coughing and breathing sounds to diagnose disease
- Patent application filed in US, Australia, Europe, China, Japan and South Korea
- Can be delivered using today's smartphones, no additional hardware required





ResApp HEALTH

Strong clinical evidence

Proof of concept study (2013)

- Funded by The Bill and Melinda Gates Foundation and The University of Queensland
- Site: Sardjito Hospital, Indonesia
- 91 patients, majority under the age of 5
- Results published in peer-reviewed journals[1,2]

Current study (started March 2015)

- Funded by ResApp
- Managed by The University of Queensland
- Sites: Joondalup Health Campus and Princess Margaret Hospital, Perth, Australia
- 340+ pediatric patients enrolled to date (continuing)

2013 Study	Sensitivity	Specificity	Accuracy
Pneumonia *vs. all respiratory*	94%	100%	**96%**
Asthma *vs. pneumonia*	100%	80%	**90%**
2015 Study	**Sensitivity**	**Specificity**	**Accuracy**
Pneumonia *vs. no respiratory*	100%	95%	**97%**
Asthma *vs. no respiratory*	97%	92%	**95%**
Bronchiolitis *vs. no respiratory*	100%	100%	**100%**
Croup *vs. no respiratory*	94%	100%	**99%**
URTI *vs. no respiratory*	100%	95%	**96%**
Pneumonia, croup or bronchiolitis *vs. URTI*	89-100%	90-95%	**89-98%**
Differential diagnosis of pneumonia, croup, URTI and bronchiolitis	92-100%	85-97%	**91-99%**

1. Abeyratne et al., Annals of Biomedical Engineering, 2013
2. Kosashi et al., IEEE Transactions in Biomedical Engineering, 2015

ResApp HEALTH

Delivery of healthcare via telehealth is one of the biggest trends in healthcare



75M
US telehealth ('evisits') consults in 2014
(Deloitte)

56%
annual growth rate
(IHS)

$12-$16B
Total US market opportunity
(Goldman Sachs, Deloitte, Teladoc)

$50B
Total global market opportunity
(Deloitte)

TELADOC · AMERICAN WELL · MDLIVE · Dr DOCTOR ON DEMAND

- Teladoc and American Well: 10M+ customers each
- Insurers such as Cigna, Aetna, UnitedHealthcare
- Employers such as Bank of America, Volvo, Yahoo!
- Hospital systems such as Mount Sinai

Walgreens · CVS/pharmacy

- Two largest US pharmacy chains have recently announced partnerships with telehealth providers

ResApp HEALTH

ResApp directly addresses the most common disease encountered by telehealth providers

The market segment addressed by ResApp is enormous

- **30%** of telehealth consults for acute respiratory disease[1]
- **22.5M** telehealth consults per year today for acute respiratory disease
- Number of telehealth consultations growing at 56% per year[2]

- **700M+** global doctor visits each year for respiratory disease[3]
  - Access through growth in telehealth plus in-person tests (in-clinic, in-hospital)

1. Uscher-Pines and Mehrotra (Health Affairs, 2014)
2. IHS
3. Based on OECD doctor visits per capita data and assuming 10% of visits are for respiratory disease (based on US data)

ResApp HEALTH

Multiple revenue streams tied to real customer value

Partnerships with telehealth providers

Direct to consumers & healthcare providers

Partnerships with device manufacturers & telcos

B2B - Per test fee

'In consultation' diagnosis.

Access partner's existing patients.

Teladoc, MDLIVE, American Well, Doctor On Demand, Health, Dr Now, 春雨移动健康, 趣医网

B2C – Install & per test fee

Download App via App Stores.

Use in home, in clinic & in hospital.

Pipeline to disease management.

Download on the App Store | GET IT ON Google play

B2B – Licensing

Reach huge installed base.

BASIS, Google, Samsung, fitbit, SK telecom, 中国移动通信 CHINA MOBILE

Big Data Insights

ResApp HEALTH

Successfully achieving key milestones in CY2015

- ☑ Australian pediatric clinical study progressing well
  - Patients 0-7 years of age with signs or symptoms of respiratory disease
  - Comparison to final clinical diagnosis as per treating team (after laboratory work and imaging)
  - 340+ patients enrolled to date
  - **Expected to have 400 patients enrolled by end of CY2015**
- ☑ Positive preliminary results from pediatric clinical study reported
  - **>95% accuracy for pneumonia, asthma, bronchiolitis, croup and URTI classification**
  - **89-99% accuracy for differential diagnosis of the most common respiratory conditions in children**
  - **Successfully demonstrated that voluntary coughs can achieve high levels of accuracy**
- ☑ AU$4M capital raising and listing on the ASX
- ☑ Appoint best-in-class FDA regulatory consultant – Experien Group (Sunnyvale, CA)
- ☐ **FDA Pre-Submission by end of CY2015**
- ☐ **Begin enrolment for Australian adult clinical study**

ResApp HEALTH

Clinical and regulatory plan to bring product to market in late CY2016



ResApp HEALTH

Summary

- Revolutionary technology – diagnosis and management of respiratory disease without the need for additional hardware
- Targeting a huge market, cough is the most common reason for visiting a doctor
- Successful clinical proof of concept funded by the Gates Foundation showed high accuracy for pneumonia and asthma diagnosis
- Multi-site clinical study progressing well with **positive preliminary results demonstrating ≥95% accuracy for pneumonia, asthma, bronchiolitis, croup and URTI versus subjects with no discernible respiratory disease and 89-99% accuracy for differential diagnosis**
- **FDA Pre-Submission planned for Q4 CY2015**
- **Fully-funded to bring product to market in late 2016**, launch via telehealth partner to reach millions of patients quickly

ResApp HEALTH